{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:36:12Z","timestamp":1770820572343,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,2,3]],"date-time":"2009-02-03T00:00:00Z","timestamp":1233619200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s11102-009-0169-z","type":"journal-article","created":{"date-parts":[[2009,2,2]],"date-time":"2009-02-02T12:13:20Z","timestamp":1233576800000},"page":"60-67","source":"Crossref","is-referenced-by-count":88,"title":["Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review"],"prefix":"10.1007","volume":"13","author":[{"given":"Gherardo","family":"Mazziotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,2,3]]},"reference":[{"key":"169_CR1","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","volume":"355","author":"S Melmed","year":"2006","unstructured":"Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355:2558\u20132573. doi: 10.1056\/NEJMra062453","journal-title":"N Engl J Med"},{"key":"169_CR2","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1210\/jc.2005-0260","volume":"90","author":"PU Freda","year":"2005","unstructured":"Freda PU, Katznelson L, van der Lely AJ et al (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90:4465\u20134473. doi: 10.1210\/jc.2005-0260","journal-title":"J Clin Endocrinol Metab"},{"key":"169_CR3","first-page":"526","volume":"85","author":"A Giustina","year":"2000","unstructured":"Giustina A, Barkan A, Casanueva FF et al (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526\u2013529. doi: 10.1210\/jc.85.2.526","journal-title":"J Clin Endocrinol Metab"},{"key":"169_CR4","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1210\/jc.2002-011841","volume":"87","author":"S Melmed","year":"2002","unstructured":"Melmed S, Casanueva FF, Cavagnini F et al (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054\u20134058. doi: 10.1210\/jc.2002-011841","journal-title":"J Clin Endocrinol Metab"},{"key":"169_CR5","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1210\/jc.2004-1093","volume":"90","author":"JS Bevan","year":"2005","unstructured":"Bevan JS (2005) The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856\u20131863. doi: 10.1210\/jc.2004-1093","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"169_CR6","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1210\/jc.2004-2466","volume":"90","author":"S Melmed","year":"2005","unstructured":"Melmed S, Sterneberg R, Cook D et al (2005) A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90(7):4405\u20134410. doi: 10.1210\/jc.2004-2466","journal-title":"J Clin Endocrinol Metab"},{"key":"169_CR7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1530\/eje.1.02036","volume":"153","author":"S Melmed","year":"2005","unstructured":"Melmed S, Casanueva F, Cavagnini F et al (2005) Consensus statement: medical management of acromegaly. Eur J Endocrinol 153:737\u2013740. doi: 10.1530\/eje.1.02036","journal-title":"Eur J Endocrinol"},{"key":"169_CR8","first-page":"3034","volume":"83","author":"CB Newman","year":"1998","unstructured":"Newman CB, Melmed S, George A et al (1998) Octreotide as primary treatment for acromegaly. J Clin Endocrinol Metab 83:3034\u20133040. doi: 10.1210\/jc.83.9.3034","journal-title":"J Clin Endocrinol Metab"},{"key":"169_CR9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/BF03349183","volume":"29","author":"M Gola","year":"2006","unstructured":"Gola M, Bonadonna S, Mazziotti G et al (2006) Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 29:86\u201393","journal-title":"J Endocrinol Invest"},{"key":"169_CR10","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/BF03349217","volume":"29","author":"A Colao","year":"2006","unstructured":"Colao A, Martino E, Cappabianca P et al (2006) First-line therapy of acromegaly: a statement of the A.L.I.C.E. (acromegaly primary medical treatment learning and improvement with continuous medical education) Study Group. J Endocrinol Invest 29:1017\u20131020","journal-title":"J Endocrinol Invest"},{"key":"169_CR11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1046\/j.0300-0664.2001.01438.x","volume":"56","author":"G Amato","year":"2002","unstructured":"Amato G, Mazziotti G, Rotondi M et al (2002) Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56:65\u201371. doi: 10.1046\/j.0300-0664.2001.01438.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"169_CR12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/BF03347378","volume":"29","author":"AP Casarini","year":"2006","unstructured":"Casarini AP, Pinto EM, Jallad RS et al (2006) Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest 29:826\u2013830","journal-title":"J Endocrinol Invest"},{"key":"169_CR13","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1210\/jc.2006-2084","volume":"92","author":"E Resmini","year":"2007","unstructured":"Resmini E, Dadati P, Ravetti JL et al (2007) Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 92:1592\u20131599. doi: 10.1210\/jc.2006-2084","journal-title":"J Clin Endocrinol Metab"},{"key":"169_CR14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1006\/phrs.1996.0095","volume":"34","author":"A Giustina","year":"1996","unstructured":"Giustina A, Zaltieri G, Negrini F, Wehrenberg WB (1996) The pharmacological aspects of the treatment of acromegaly. Pharmacol Res 34:247\u2013268. doi: 10.1006\/phrs.1996.0095","journal-title":"Pharmacol Res"},{"key":"169_CR15","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1210\/jc.2008-0027","volume":"93","author":"RD Murray","year":"2008","unstructured":"Murray RD, Melmed S (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93:2957\u20132968","journal-title":"J Clin Endocrinol Metab"},{"issue":"8, Suppl 1","key":"169_CR16","first-page":"21","volume":"45","author":"DH Coy","year":"1996","unstructured":"Coy DH, Taylor JE (1996) Receptor-specific somatostatin analogs: correlations with biological activity. Metabolism 45(8, Suppl 1):21\u201323. doi: 10.1016\/S0026-0495(96)90073-6","journal-title":"Metabolism"},{"key":"169_CR17","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1177\/0091270005277936","volume":"45","author":"B Astruc","year":"2005","unstructured":"Astruc B, Marbach P, Bouterfa H et al (2005) Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 45:836\u2013844. doi: 10.1177\/0091270005277936","journal-title":"J Clin Pharmacol"},{"key":"169_CR18","first-page":"145","volume":"79","author":"I Morange","year":"1994","unstructured":"Morange I, De Boisvilliers F, Chanson P et al (1994) Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 79:145\u2013151. doi: 10.1210\/jc.79.1.145","journal-title":"J Clin Endocrinol Metab"},{"key":"169_CR19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1530\/eje.0.1310020","volume":"131","author":"J Marek","year":"1994","unstructured":"Marek J, H\u00e1na V, Krsek M et al (1994) Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol 131:20\u201326. doi: 10.1530\/eje.0.1310020","journal-title":"Eur J Endocrinol"},{"key":"169_CR20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1530\/eje.0.1320320","volume":"132","author":"P Caron","year":"1995","unstructured":"Caron P, Cogne M, Gusthiot-Joudet B et al (1995) Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol 132:320\u2013325. doi: 10.1530\/eje.0.1320320","journal-title":"Eur J Endocrinol"},{"key":"169_CR21","first-page":"18","volume":"82","author":"P Caron","year":"1997","unstructured":"Caron P, Morange-Ramos I, Cogne M, Jaquet P (1997) Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 82:18\u201322. doi: 10.1210\/jc.82.1.18","journal-title":"J Clin Endocrinol Metab"},{"key":"169_CR22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1365-2362.1997.1190659.x","volume":"27","author":"M Giusti","year":"1997","unstructured":"Giusti M, Ciccarelli E, Dallabonzana D et al (1997) Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Clin Invest 27:277\u2013284. doi: 10.1046\/j.1365-2362.1997.1190659.x","journal-title":"Eur J Clin Invest"},{"key":"169_CR23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/BF03345477","volume":"22","author":"A Colao","year":"1999","unstructured":"Colao A, Marzullo P, Ferone D et al (1999) Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest 22:40\u201347","journal-title":"J Endocrinol Invest"},{"key":"169_CR24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF03343583","volume":"22","author":"M Suliman","year":"1999","unstructured":"Suliman M, Jenkins R, Ross R et al (1999) Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. J Endocrinol Invest 22:409\u2013418","journal-title":"J Endocrinol Invest"},{"key":"169_CR25","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1530\/eje.0.1430577","volume":"143","author":"JA Verhelst","year":"2000","unstructured":"Verhelst JA, Pedroncelli AM, Abs R et al (2000) Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 143:577\u2013584. doi: 10.1530\/eje.0.1430577","journal-title":"Eur J Endocrinol"},{"key":"169_CR26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1055\/s-2007-978625","volume":"32","author":"S Cannav\u00f2","year":"2000","unstructured":"Cannav\u00f2 S, Squadrito S, Curt\u00f2 L et al (2000) Results of a two-year treatment with slow release lanreotide in acromegaly. Horm Metab Res 32:224\u2013229. doi: 10.1055\/s-2007-978625","journal-title":"Horm Metab Res"},{"key":"169_CR27","first-page":"4099","volume":"85","author":"R Baldelli","year":"2000","unstructured":"Baldelli R, Colao A, Razzore P et al (2000) Two-year follow-up of acromegalic patients treated with slow release lanreotide (30\u00a0mg). J Clin Endocrinol Metab 85:4099\u20134103. doi: 10.1210\/jc.85.11.4099","journal-title":"J Clin Endocrinol Metab"},{"key":"169_CR28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1012832230598","volume":"3","author":"R Cozzi","year":"2000","unstructured":"Cozzi R, Barausse M, Sberna M et al (2000) Lanreotide 60\u00a0mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly. Pituitary 3:231\u2013238. doi: 10.1023\/A:1012832230598","journal-title":"Pituitary"},{"key":"169_CR29","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1055\/s-2001-17910","volume":"33","author":"S Cannav\u00f2","year":"2001","unstructured":"Cannav\u00f2 S, Squadrito S, Curt\u00f2 L et al (2001) Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma. Horm Metab Res 33:618\u2013624. doi: 10.1055\/s-2001-17910","journal-title":"Horm Metab Res"},{"key":"169_CR30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF03343849","volume":"24","author":"R Attanasio","year":"2001","unstructured":"Attanasio R, Barausse M, Cozzi R (2001) GH\/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide. J Endocrinol Invest 24:209\u2013216","journal-title":"J Endocrinol Invest"},{"key":"169_CR31","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1210\/jc.2003-030266","volume":"88","author":"R Attanasio","year":"2003","unstructured":"Attanasio R, Baldelli R, Pivonello R et al (2003) Lanreotide 60\u00a0mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 88:5258\u20135265. doi: 10.1210\/jc.2003-030266","journal-title":"J Clin Endocrinol Metab"},{"key":"169_CR32","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1365-2265.2003.01741.x","volume":"58","author":"T Lucas","year":"2003","unstructured":"Lucas T, Astorga R, Catal\u00e1 M, Spanish Multicentre Lanreotide Study Group on Acromegaly (2003) Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf) 58:471\u2013481. doi: 10.1046\/j.1365-2265.2003.01741.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"169_CR33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/eje.0.1500489","volume":"150","author":"SW Thiel van","year":"2004","unstructured":"van Thiel SW, Romijn JA, Biermasz NR et al (2004) Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 150:489\u2013495. doi: 10.1530\/eje.0.1500489","journal-title":"Eur J Endocrinol"},{"key":"169_CR34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1530\/eje.0.1510317","volume":"151","author":"O Alexopoulou","year":"2004","unstructured":"Alexopoulou O, Abrams P, Verhelst J et al (2004) Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 151:317\u2013324. doi: 10.1530\/eje.0.1510317","journal-title":"Eur J Endocrinol"},{"key":"169_CR35","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2265.2007.02878.x","volume":"67","author":"JC Maiza","year":"2007","unstructured":"Maiza JC, Vezzosi D, Matta M et al (2007) Long-term (up to 18\u00a0years) effects on GH\/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 67:282\u2013289. doi: 10.1111\/j.1365-2265.2007.02878.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"169_CR36","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1365-2265.2007.03139.x","volume":"68","author":"N Karavitaki","year":"2008","unstructured":"Karavitaki N, Turner HE, Adams CB et al (2008) Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf) 68:970\u2013975. doi: 10.1111\/j.1365-2265.2007.03139.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"169_CR37","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4158\/EP.14.7.846","volume":"14","author":"R Attanasio","year":"2008","unstructured":"Attanasio R, Lanzi R, Losa M et al (2008) Effects of lanreotide Autogel on growth hormone, insulin-like growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract 14:846\u2013855","journal-title":"Endocr Pract"},{"key":"169_CR38","doi-asserted-by":"crossref","unstructured":"Colao A, Auriemma RS, Rebora A et al (2008) Significant tumor shrinkage after lanreotide autogel-120\u00a0mg as first-line treatment of acromegaly. Clin Endocrinol (Oxf) (Dec):15 Epub ahead of print","DOI":"10.1111\/j.1365-2265.2008.03503.x"},{"key":"169_CR39","first-page":"1688","volume":"10","author":"K Sharma","year":"1996","unstructured":"Sharma K, Patel YC, Srikant CB (1996) Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 10:1688\u20131696. doi: 10.1210\/me.10.12.1688","journal-title":"Mol Endocrinol"},{"key":"169_CR40","first-page":"2976","volume":"86","author":"DC Danila","year":"2001","unstructured":"Danila DC, Haidar JN, Zhang X et al (2001) Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab 86:2976\u20132981. doi: 10.1210\/jc.86.7.2976","journal-title":"J Clin Endocrinol Metab"},{"key":"169_CR41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0889-8529(05)70057-8","volume":"28","author":"MJ Naidich","year":"1999","unstructured":"Naidich MJ, Russell EJ (1999) Current approaches to imaging of the sellar region and pituitary. Endocrinol Metab Clin North Am 28:45\u201379. doi: 10.1016\/S0889-8529(05)70057-8","journal-title":"Endocrinol Metab Clin North Am"},{"key":"169_CR42","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1210\/jcem-67-5-1040","volume":"67","author":"AL Barkan","year":"1988","unstructured":"Barkan AL, Lloyd RV, Chandler WF et al (1988) Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201\u2013995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67:1040\u20131048","journal-title":"J Clin Endocrinol Metab"},{"key":"169_CR43","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1210\/jc.2005-2110","volume":"91","author":"A Colao","year":"2006","unstructured":"Colao A, Pivonello R, Auriemma RS et al (2006) Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 91:2112\u20132118. doi: 10.1210\/jc.2005-2110","journal-title":"J Clin Endocrinol Metab"},{"key":"169_CR44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/A:1026225625897","volume":"6","author":"ME Molitch","year":"2003","unstructured":"Molitch ME (2003) Dopamine resistance of prolactinomas. Pituitary 6:19\u201327. doi: 10.1023\/A:1026225625897","journal-title":"Pituitary"},{"key":"169_CR45","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1210\/jc.2006-2547","volume":"9","author":"P Maison","year":"2007","unstructured":"Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P (2007) Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab 9:1743\u20131747. doi: 10.1210\/jc.2006-2547","journal-title":"J Clin Endocrinol Metab"},{"key":"169_CR46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11102-007-0062-6","volume":"11","author":"L Marinis De","year":"2008","unstructured":"De Marinis L, Bianchi A, Mazziotti G et al (2008) The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary 11:13\u201320. doi: 10.1007\/s11102-007-0062-6","journal-title":"Pituitary"},{"key":"169_CR47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.2007-0036","volume":"29","author":"A Giustina","year":"2008","unstructured":"Giustina A, Mazziotti G, Canalis E (2008) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29:535\u2013559. doi: 10.1210\/er.2007-0036","journal-title":"Endocr Rev"},{"key":"169_CR48","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM199601253340408","volume":"334","author":"SW Lamberts","year":"1996","unstructured":"Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ (1996) Octreotide. N Engl J Med 334:246\u2013254. doi: 10.1056\/NEJM199601253340408","journal-title":"N Engl J Med"},{"key":"169_CR49","first-page":"717","volume":"19","author":"A Giustina","year":"1998","unstructured":"Giustina A, Veldhuis JD (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717\u2013797. doi: 10.1210\/er.19.6.717","journal-title":"Endocr Rev"},{"key":"169_CR50","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2265.2003.01811.x","volume":"59","author":"T Florio","year":"2003","unstructured":"Florio T, Thellung S, Corsaro A et al (2003) Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf) 59:115\u2013128. doi: 10.1046\/j.1365-2265.2003.01811.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"169_CR51","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pharmthera.2004.02.002","volume":"102","author":"P Dasgupta","year":"2004","unstructured":"Dasgupta P (2004) Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 102:61\u201385. doi: 10.1016\/j.pharmthera.2004.02.002","journal-title":"Pharmacol Ther"},{"key":"169_CR52","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1365-2265.2005.02372.x","volume":"63","author":"M Bronstein","year":"2005","unstructured":"Bronstein M, Musolino N, Jallad R et al (2005) Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120\u00a0mg every 28\u00a0days. Clin Endocrinol (Oxf) 63:514\u2013519. doi: 10.1111\/j.1365-2265.2005.02372.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"169_CR53","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1210\/jcem.87.1.8153","volume":"87","author":"P Caron","year":"2002","unstructured":"Caron P, Beckers A, Cullen DR et al (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 87:99\u2013104. doi: 10.1210\/jc.87.1.99","journal-title":"J Clin Endocrinol Metab"},{"key":"169_CR54","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/eje.0.1500473","volume":"150","author":"SG Ashwell","year":"2004","unstructured":"Ashwell SG, Bevan JS, Edwards OM et al (2004) The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 150:473\u2013480. doi: 10.1530\/eje.0.1500473","journal-title":"Eur J Endocrinol"},{"key":"169_CR55","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2265.2004.02045.x","volume":"60","author":"P Caron","year":"2004","unstructured":"Caron P, Bex M, Cullen DR et al (2004) One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 60:734\u2013740. doi: 10.1111\/j.1365-2265.2004.02045.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"169_CR56","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2265.2006.02450.x","volume":"64","author":"P Caron","year":"2006","unstructured":"Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM (2006) Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 64:209\u2013214. doi: 10.1111\/j.1365-2265.2006.02450.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"169_CR57","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2265.2006.02595.x","volume":"65","author":"T Lucas","year":"2006","unstructured":"Lucas T, Astorga R, Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly (2006) Efficacy of lanreotide Autogel administered every 4\u20138\u00a0weeks in patients with acromegaly previously responsive to lanreotide microparticles 30\u00a0mg: a phase III trial. Clin Endocrinol (Oxf) 65:320\u2013326. doi: 10.1111\/j.1365-2265.2006.02595.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"169_CR58","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1530\/EJE-07-0366","volume":"157","author":"P Abrams","year":"2007","unstructured":"Abrams P, Alexopoulou O, Abs R, Maiter D, Verhelst J (2007) Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. Eur J Endocrinol 157:571\u2013577. doi: 10.1530\/EJE-07-0366","journal-title":"Eur J Endocrinol"},{"key":"169_CR59","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2265.2007.02917.x","volume":"67","author":"CL Ronchi","year":"2007","unstructured":"Ronchi CL, Boschetti M, Degli Uberti EC et al (2007) Efficacy of a slow-release formulation of lanreotide (Autogel) 120\u00a0mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf) 67:512\u2013519","journal-title":"Clin Endocrinol (Oxf)"},{"key":"169_CR60","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2265.2007.03044.x","volume":"68","author":"JS Bevan","year":"2008","unstructured":"Bevan JS, Newell-Price J, Wass JA et al (2008) Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf) 68:343\u2013349","journal-title":"Clin Endocrinol (Oxf)"},{"key":"169_CR61","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2265.2007.03067.x","volume":"68","author":"M Andries","year":"2008","unstructured":"Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M (2008) A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf) 68:473\u2013480","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-009-0169-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-009-0169-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-009-0169-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T23:59:10Z","timestamp":1633046350000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-009-0169-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,3]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["169"],"URL":"https:\/\/doi.org\/10.1007\/s11102-009-0169-z","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,3]]}}}